Literature DB >> 34250407

Interplay Between Class II HLA Genotypes and the Microbiome and Immune Phenotypes in Individuals With PTEN Hamartoma Tumor Syndrome.

Margaret Jia1, Naseer Sangwan2, Alice Tzeng1,3, Charis Eng1,3,4,5,6,7.   

Abstract

We evaluate potential contributors to the development of autoimmunity and other phenotypes consistent with immune dysregulation in individuals with germline mutations in the tumor suppressor gene PTEN in this observational report.
MATERIALS AND METHODS: Illumina sequencing of bacterial and fungal microbes was carried out on patient-donated fecal samples in a cohort of 67 patients with pathogenic germline PTEN mutations, including 41 individuals with autoimmunity and/or phenotypes consistent with immune dysregulation (cases) and 26 individuals without (controls). From these data, we measured differences in alpha and beta diversity between cases and controls and identified differentially abundant bacterial and fungal taxa using phyloseq and MicrobiomeSeq packages in R. We analyzed correlations between these taxa and specific HLA genotypes, along with correlations between HLA diversity and microbial diversity, by conducting high-resolution HLA genotyping at four class II loci (DRB1, DRB345, DQA1, and DQB1).
RESULTS: We found that alpha diversity distributions for both bacterial and fungal genera were statistically different between cases and controls. We identified differentially abundant bacterial and fungal taxa between cases and controls. Network analysis of differentially abundant bacterial taxa revealed some co-varying bacterial genera. We additionally found significant correlations between certain HLA genotypes and certain taxa and significant correlations between HLA diversity and alpha diversity.
CONCLUSION: PTEN-associated immune phenotypes might be influenced by the gut microbiome, and class II HLA molecules, in part, crosstalk with the gut microbiome. These preliminary observations should lay the groundwork for future studies to ultimately derive clinical measures, which could use gut microbiome and HLA molecule biomarkers to predict, and perhaps prevent, immunity and inflammation in patients predisposed to cancer because of germline PTEN mutations.
© 2021 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34250407      PMCID: PMC8232567          DOI: 10.1200/PO.20.00374

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  41 in total

1.  Bifidobacteria can protect from enteropathogenic infection through production of acetate.

Authors:  Shinji Fukuda; Hidehiro Toh; Koji Hase; Kenshiro Oshima; Yumiko Nakanishi; Kazutoshi Yoshimura; Toru Tobe; Julie M Clarke; David L Topping; Tohru Suzuki; Todd D Taylor; Kikuji Itoh; Jun Kikuchi; Hidetoshi Morita; Masahira Hattori; Hiroshi Ohno
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

Review 2.  Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes.

Authors:  Li Wen; Andrew Duffy
Journal:  J Nutr       Date:  2017-06-14       Impact factor: 4.798

3.  Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.

Authors:  M G Butler; M J Dasouki; X-P Zhou; Z Talebizadeh; M Brown; T N Takahashi; J H Miles; C H Wang; R Stratton; R Pilarski; C Eng
Journal:  J Med Genet       Date:  2005-04       Impact factor: 6.318

4.  The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.

Authors:  Patrick M Smith; Michael R Howitt; Nicolai Panikov; Monia Michaud; Carey Ann Gallini; Mohammad Bohlooly-Y; Jonathan N Glickman; Wendy S Garrett
Journal:  Science       Date:  2013-07-04       Impact factor: 47.728

5.  Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice.

Authors:  Ritika Jaini; Matthew G Loya; Alexander T King; Stetson Thacker; Nicholas B Sarn; Qi Yu; George R Stark; Charis Eng
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

6.  Major histocompatibility complex heterozygote superiority during coinfection.

Authors:  Erin E McClelland; Dustin J Penn; Wayne K Potts
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 7.  Desulfovibrio desulfuricans bacteremia and review of human Desulfovibrio infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Victoria A Peraino; Sally A Cross
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

8.  Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis.

Authors:  Tessalia Diniz Luerce; Ana Cristina Gomes-Santos; Clarissa Santos Rocha; Thais Garcias Moreira; Déborah Nogueira Cruz; Luísa Lemos; Adna Luciana Sousa; Vanessa Bastos Pereira; Marcela de Azevedo; Kátia Moraes; Denise Carmona Cara; Jean Guy LeBlanc; Vasco Azevedo; Ana Maria Caetano Faria; Anderson Miyoshi
Journal:  Gut Pathog       Date:  2014-07-29       Impact factor: 4.181

Review 9.  The gut microbiome: Relationships with disease and opportunities for therapy.

Authors:  Juliana Durack; Susan V Lynch
Journal:  J Exp Med       Date:  2018-10-15       Impact factor: 14.307

10.  Does MHC heterozygosity influence microbiota form and function?

Authors:  M A Wadud Khan; W Zac Stephens; Ahmed Dawood Mohammed; June Louise Round; Jason Lee Kubinak
Journal:  PLoS One       Date:  2019-05-16       Impact factor: 3.240

View more
  1 in total

1.  Altered Gut Microbiota in Patients With Peutz-Jeghers Syndrome.

Authors:  Sui Wang; Gang Huang; Jue-Xin Wang; Lin Tian; Xiu-Li Zuo; Yan-Qing Li; Yan-Bo Yu
Journal:  Front Microbiol       Date:  2022-07-13       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.